Synthesis and substrate properties towards HIV-1 reverse transcriptase of new diphosphate analogues of 9-[(2-phosphonomethoxy)ethyl]adenine

Wolfgang Hg Laux, Stephane Priet, Karine Alvarez, Suzanne Peyrottes, Christian Perigaud

To cite this version:

HAL Id: hal-02094536
https://amu.hal.science/hal-02094536
Submitted on 9 Apr 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License
Synthesis and substrate properties towards HIV-1 reverse transcriptase of new diphosphate analogues of 9-[(2-phosphonomethoxy)ethyl]adenine

Wolfgang HG Laux1, Stéphane Priet2, Karine Alvarez2, Suzanne Peyrottes1 and Christian Périgaud1

Abstract

Background: The replacement of β,γ-pyrophosphate by β,γ-phosphonate moieties within the triphosphate chain of 5′-triphosphate nucleoside analogues was previously studied for various antiviral nucleoside analogues such as AZT and 2′,3′-dideoxynucleosides. Thus, it has been shown that these chemical modifications could preserve, in some cases, the terminating substrate properties of the triphosphate analogue for HIV-RT. Herein, we aimed to study such 5′-triphosphate mimics based on the scaffold of the well-known antiviral agent 9-[(2-phosphonomethoxy)ethyl]adenine (PMEA, Adefovir).

Methods: Synthesis involved coupling of a morpholidate derivative of PMEA with appropriate pyrophosphoryl analogues. The relative efficiencies of incorporation of the studied diphosphate phosphonates were measured using subtype B WT HIV-1 RT in an in vitro susceptibility assay, in comparison to the parent nucleotide analogue (PMEApp).

Results: Searching for nucleoside 5′-triphosphate mimics, we have synthesized and studied a series of diphosphate analogues of PMEA bearing non hydrolysable bonds between the and phosphorus atoms. We also examined their relative inhibitory capacity towards HIV-1 reverse transcriptase in comparison to the parent nucleotide analogue (PMEApp). Only one of them appeared as a weak inhibitor (IC50 = 403.0 ± 75.5 μM) and proved to be less effective than PMEApp (IC50 = 6.4 ± 0.8 μM).

Conclusion: PMEA diphosphoryl derivatives were designed as potential substrates and/or inhibitors of various viral polymerases. These modifications dramatically affect their ability to inhibit HIV-RT.

Keywords

(phosphomethoxy)ethyl]adenine, phosphonate diphosphate analogues, HIV-1 reverse transcriptase, antiviral

Introduction

The acyclic nucleoside phosphonate 9-{2-(phosphonomethoxy)ethyl]adenine (PMEA, Figure 1) exhibits a broad-spectrum activity against different types of DNA viruses and retroviruses. Its orally bioavailable form, the bis(pivaloyloxyethyl) prodrug (bis(POM)PMEA, Adefovir dipivoxil), has been approved for the treatment of chronic hepatitis B and other types of prodrugs are still under investigations. To achieve its inhibitory effect on viral synthesis, PMEA must be converted intracellularly to its active diphosphorylated metabolite, PMEApp (Figure 1). PMEApp has been described to interact as an alternative substrate and as a competitive inhibitor of both herpes simplex type 1 (HSV-1) DNA polymerase and reverse transcriptases. Variable inhibitory effects on human cellular DNA polymerases were observed, especially against DNA polymerase for which Ki value was in the same range as dATP.

1Institut des Biomolécules Max Mousseron (IBMM), UMR 5247 CNRS, Univ. Montpellier, ENSCM, Campus Triotel, Montpellier, Cedex, France
2Laboratoire AFMB, AMU, CNRS, UMR 7257, Groupe “Chimie Médicinale Antivirale”, Marseille, Cedex, France

Corresponding author:
Christian Périgaud, Institut des Biomolécules Max Mousseron (IBMM), UMR 5247 CNRS, Univ. Montpellier, ENSCM, Campus Triotel, cc1704, Place Eugène Bataillon, Montpellier 34095, Cedex 5, France. Email: christian.perigaud@umontpellier.fr

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
When compared to the affinity of PMEApp for HIV-RT (with $K_i$ value in the nanomolar range), it may explain the antiviral selectivity of parent phosphonate.

As part of a research program, we decided to synthesize new nucleoside $5'$-triphosphate mimics based on the PMEA scaffold and incorporating chemical modifications of the Pβ–O–Pγ phosphoester bonds. Replacement of the anhydride oxygen with isosteric groups leading to non-hydrolysable bonds, the resulting analogues were designed as biological tools for the study of substrate properties of cellular and/or viral enzymatic systems, as well as new potential therapeutic agents. Base on previously published works on related topic, requirements in the design of modified triphosphate analogues emerged: (i) the anhydride bond between β- and γ-phosphates, which is unaffected during the DNA biosynthesis, could be replaced with non-hydrolysable bond; (ii) similar modification could also be introduced between the $5'$-position of sugar and the phosphorus atom; (iii) the anhydride bond between α- and β-P atoms should be preserved in order to provide the possibility of the mimetic to interact with targeted polymeric substrate.

In this respect, PMEApp constitutes an attractive model to study chemical modifications on the pyrophosphoryl residue due to its phosphonate structure, characterized by a stable P-C bond (toward phosphohydrolase-hydrolysis) between acyclic nucleoside moiety and α-phosphorus atom, and its broad and high affinity for viral polymerases. Herein, we report the full accounts of the synthesis of compounds 1b-j and their study as terminating substrates in the DNA chain elongation catalyzed by human immunodeficiency virus (HIV) reverse transcriptase.

**Experimental section**

**Material and methods**

$^1$H NMR (250 MHz) and $^{13}$C NMR (100 MHz) spectra were recorded with proton decoupling at ambient temperature. Chemical shifts ($\delta$) are quoted in parts per million (ppm) referenced to the residual solvent peak chloroform (CDCl$_3$) at 7.26 ppm and 77.0 ppm, deuterium oxide (D$_2$O) at 4.63 ppm relative to tetramethylsilane (TMS). COSY experiments were performed in order to confirm proton assignments as well as 2D $^1$H,$^{13}$C heteronuclear COSY for the attribution of $^{13}$C signals. $^{31}$P NMR spectra were recorded at ambient temperature at 100 MHz. Chemical shifts are reported relative to external phosphoric acid (H$_3$PO$_4$). $^{19}$F NMR spectra were recorded at ambient temperature at 235 MHz. Chemical shifts are reported relative to external trichlorofluoromethane (CFCl$_3$). Coupling constants, $J$, are given in Hertz. FAB mass spectra were recorded in the negative-ion mode using glycerol/thioglycerol (1:1, v/v, G-T) as matrix. Only nominal mass of ions corresponding to the mass of the lightest chlorine or bromine isotopes is given. However, the halogen-isotope peak intensity patterns were ascertained and they agreed with the formula of the ions. Thin layer chromatography was performed on precoated aluminum sheets of Silica Gel 60 F$_{254}$ (Merck, Art. 5554), visualization of products was accomplished by UV absorbance followed by spraying with Hanes molybdate reagent. Column chromatography was carried out on Silica Gel 60 (Merck, Art. 9385). Analytical HPLC studies were performed using a reverse-phase analytical column (Nucleosil, C18, 150 x 4.6 mm, 5 m) equipped with a prefilter, a precolumn (Nucleosil, C18, 5 m), and a photodiode array detector. Compounds were eluted under isocratic conditions with 0.4% acetonitrile in 50 mM triethylammonium acetate buffer with a flow rate of 1 mL/min. All moisture sensitive reactions were carried out in anhydrous conditions under argon atmosphere using oven-dried glassware. Solvents were dried and distilled prior to use and solids were dried over P$_2$O$_5$ under reduced pressure at rt.

**Chemistry**

9-[(2-Phosphomethoxy)ethyl]-adenine (PMEA) and its phosphomorpholidate derivative 2 were synthesized according to a published procedure. The tributylammonium salts of pyrophosphate 3a and diphosphonic acids 3b-d were obtained from their commercially available forms: tetra sodium pyrophosphate decahydrate, tetra sodium imididiphosphonate, methanediphosphonic acid and 1-hydroxyethylidene diphosphonic acid, respectively. The halomethylidene diphosphonic acids 3e-j were obtained from their ethyl esters precursors following a usual way and stored as sodium forms after passage over a Dowex 50WX2 cation exchange resin column and freeze-drying. Tetraethyl

![Figure 1](image-url)
methylene diphosphonate 4 was commercially available. The halomethylene diphosphonate esters 5e, 5g, 6f and 6h were prepared using literature methods. Detailed description of experimental procedures and compound characterization are provided as supplementary data.

**In vitro drug susceptibility assays with recombinant subtype B WT HIV-1 RT**

The p66RTB gene construct allowing the bacterial expression of the wild-type (WT) HIV-1 RT was described elsewhere. The recombinant clade B WT HIV-1 RT was co-expressed with HIV-1 protease in *Escherichia coli* in order to obtain p66/p51 heterodimers, which were later purified using affinity chromatography. Enzymes were quantitated by active-site titration before biochemical studies.

Standard RT activity was assayed using 250 μg/mL of activated calf thymus DNA (GE Healthcare). To determine IC50 values, reactions were performed with 10 nM enzyme and 5 μL each dNTP as a mixture (dATP, dCTP, dGTP, dTTP) containing 100 μCi/mmol of [3H]-labelled deoxythymidine 5'-triphosphate (Perkin Elmer), for 15 min with increasing amounts of phosphonate, compounds 1a (PMEApp as reference), 1c, 1e to 1j. Each aliquot was spotted in duplicate on DE81 ion-exchange paper discs. Paper discs were washed twice with 0.3 M ammonium formate, pH 8.0, twice with water and once with ethanol, and then dried and transferred into sample bags. Scintillation fluid was added and the radioactivity bound to the discs was determined by liquid scintillation counting with MicroBeta Trilux Counter. Values of IC50 are the average from at least three independent experiments and were determined using Kaleidagraph data.

**Molecular modeling of HIV-1 RT in complex with diphosphate phosphonate analogues 1c, 1e, 1g, 1i**

All models were based on the X-ray structure of the RT in complex with dsDNA and incoming PMPApp (PDB code 1T05). The UCSF Chimera software (PMID: 15264254) was used to replace the PMP – moiety by the PME – equivalent. Moreover, the oxygen of the βγ bridge of the diphosphate phosphonate PMPApp was replaced by CH2 (compound 1c), CCl2 (compound 1e), CBr2 (compound 1g) and CF2 (compound 1i) groups.

**Results**

The synthesis of PMEA diphosphate 1a and its mimetics 1b-j was carried out according to a general procedure (Scheme 1), which requires preliminary preparation of the phosphoromorpholidate derivative 2 of PMEA. This was accomplished by usual reaction of PMEA with morpholine and N,N'-dicyclohexylcarbodiimide as activating agent. Isolated as its 4-morpholine N,N'-dicyclohexyloxycarbodiimide salt, 2 was further condensed with the appropriate tributylammonium salts of the diphosphonic acids 3b-j. The imido- and methylene-diphosphonate reagents 3b-d were commercially available as sodium or acidic forms. The halomethylidene diphosphonic acids 3e-h were prepared from the commercial tetraethyl methylenediphosphonate, following a published procedure. Preparation of the fluorinated diphosphonic acids 3i, j has previously been described from direct halogenation of tetra alkyl methylenediphosphonates or nucleophilic substitution of an appropriate halomethylphosphonate derivative by a phosphate anion.

Moreover, in contrast to the dichloro- and dibromo-analogues (3e-h), nucleophilic dehalogenation of difluoromethylene-diphosphonates into the corresponding monofluoro esters by conventional methods was unsuccessful. In such conditions, P–C bond cleavage was observed resulting in the formation of dialkyl difluoromethylphosphonates. Thus, we decided to select the first approach (i.e. direct halogenation) leading in one step to a mixture of the mono- and difluoro- compounds through reaction of electrophilic fluorinating reagents with the carbanions.

---

**Scheme 1.** Final step in the synthesis of PMEApp 1a, and target diphosphate analogues 1b-j.
of alkyl methyldenediphosphonates. Reported methodologies used perchloryl fluoride \( \text{19} \) or acetyl hypofluorite.\(^{30} \) Herein, \( N \)-fluorobenzenesulfonimide was chosen as commercially available and easy handling fluorinating reagent.\(^{31} \) Consequently, tetraethyl methylenediphosphonate \( 4 \) was deprotonated by the action of potassium tert-butoxide and treated with \( N \)-fluorobenzene-sulfonimide (Scheme 2). Purification of the resulting mixture on flash silica gel chromatography yielded 29% of the starting material \( 4 \) and 31% of each desired mono- and dihalogenated species \( 5i \) and \( 6j \), respectively. Saponification of the tetraethyl fluoromethylenediphosphonate esters \( 5i \) and \( 6j \) was carried out using bromotrimethylsilane to give rise to the fluorinated diphosphonic acids \( 3i, j \).

Crude reaction of the phosphoromorpholidate derivative of \( \text{PMEA} \ 2 \) with pyrophosphate \( 3a \) or the appropriate tributylammonium salts of the diphosphonic acids \( 3b-j \) was firstly purified by a Dowex 1X2 chromatography using a gradient of aqueous lithium chloride in 0.01 M hydrochloric acid.\(^{18} \) Then, DEAE-Sephadex A25 chromatography gave \( \text{PMEA} \) diphosphate \( 1a \) and its mimetics \( 1b-j \). The low yield obtained for derivative \( 1b \) (18%) was probably due to the chemical instability of the imido functionality\(^{32} \) during purification step at acidic pH. Structures of the different mimetics of \( \text{PMEA} \) diphosphate were assigned on the basis of their NMR data (Tables 1 and 2), MS and UV spectra. Purity was checked by analytical high pressure liquid chromatography (HPLC) and high resolution mass spectra (HRMS).

To evaluate the inhibitory activity of diphosphate phosphonates \( 1a, 1c, 1e \) to \( 1j \) on the reverse transcriptase (RT) of HIV-1, their relative efficiencies of incorporation were measured using subtype B WT HIV-1 RT in an in vitro susceptibility assay. The calculated 50% inhibitory concentration (IC\(_{50}\)) values obtained in this assay showed that \( \text{PMEApp} \ 1a \) is active (IC\(_{50} = 6.4 \pm 0.8 \mu M \)), this value was in agreement with literature data,\(^{33} \) whereas the diphosphate phosphonate analogues are truly less potent (IC\(_{50} > 1000 \mu M \) or IC\(_{50} = 403.0 \pm 75.5 \mu M \) for compound \( 1i \)).

### Discussion

The synthesis of new mimics of \( \text{PMEApp} \) incorporating non hydrolysable bond between the \( \beta \)- and \( \gamma \)-P atoms has been carried out by reaction of the morpholidate derivative of \( \text{PMEA} \ 2 \) with the appropriate diphosphinic acids \( 3b-j \) (Scheme 1). The target diphosphate analogues \( 1b-j \) were isolated as lithium forms in 18–65% yields.

The \( ^{31}P \) NMR spectra of the mimetic phosphonates \( 1b-j \) showed characteristic downfield shifts which permitted, from a straightforward comparison with literature data, the direct assignment of resonances for \( \alpha-, \) \( \beta-, \) and \( \gamma \)-P atoms.

### Table 1. Selected \( ^{31}P \) NMR data of the new \( \text{PMEA} \) diphosphate mimetics \( 1b-j \).

<table>
<thead>
<tr>
<th>Compound</th>
<th>( \delta P_\alpha ) (ppm)</th>
<th>( \delta P_\beta ) (ppm)</th>
<th>( \delta P_\gamma ) (ppm)</th>
<th>( ^2J_\beta\beta ) (Hz)</th>
<th>( ^2J_\beta\gamma ) (Hz)</th>
</tr>
</thead>
<tbody>
<tr>
<td>( 1a )</td>
<td>9.4</td>
<td>-19.6</td>
<td>-4.3</td>
<td>24.9</td>
<td>18.1</td>
</tr>
<tr>
<td>( 1b )</td>
<td>9.7</td>
<td>-6.2</td>
<td>0.7</td>
<td>25.6</td>
<td>5.2</td>
</tr>
<tr>
<td>( 1c )</td>
<td>9.2</td>
<td>14.7</td>
<td>13.7</td>
<td>29.2</td>
<td>7.5</td>
</tr>
<tr>
<td>( 1d )</td>
<td>9.9</td>
<td>16.4</td>
<td>17.6</td>
<td>36.1</td>
<td>32.2</td>
</tr>
<tr>
<td>( 1e )</td>
<td>9.8</td>
<td>3.9</td>
<td>9.5</td>
<td>34.9</td>
<td>15.8</td>
</tr>
<tr>
<td>( 1f )</td>
<td>9.4</td>
<td>7.9</td>
<td>10.3</td>
<td>31.1</td>
<td>5.2</td>
</tr>
<tr>
<td>( 1g )</td>
<td>9.3</td>
<td>7.1</td>
<td>9.9</td>
<td>31.2</td>
<td>3.9</td>
</tr>
<tr>
<td>( 1h )</td>
<td>10.1</td>
<td>-3.8</td>
<td>3.9</td>
<td>33.8</td>
<td>59.0</td>
</tr>
<tr>
<td>( 1i )</td>
<td>9.5</td>
<td>6.8</td>
<td>8.6</td>
<td>31.3</td>
<td>12.2</td>
</tr>
</tbody>
</table>

### Table 2. Selected \( ^{13}C \) and \( ^{19}F \) NMR data of the new \( \text{PMEA} \) diphosphate mimetics \( 1c-j \).

<table>
<thead>
<tr>
<th>Compound</th>
<th>( \delta C ) (ppm)</th>
<th>( \delta F ) (ppm)</th>
<th>( ^2J_{FC} ) (Hz)</th>
<th>( ^2J_{FP\beta} ) (Hz)</th>
<th>( ^2J_{FP\gamma} ) (Hz)</th>
</tr>
</thead>
<tbody>
<tr>
<td>( 1c )</td>
<td>30.8</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>( 1d )</td>
<td>72.4</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>( 1e )</td>
<td>78.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>( 1f )</td>
<td>49.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>( 1g )</td>
<td>57.4</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>( 1h )</td>
<td>38.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>( 1i )</td>
<td>118.7</td>
<td>-120.3</td>
<td>273.7</td>
<td>87.7</td>
<td>79.4</td>
</tr>
<tr>
<td>( 1j )</td>
<td>89.3</td>
<td>-218.6</td>
<td>180.5</td>
<td>64.8</td>
<td>55.6</td>
</tr>
</tbody>
</table>
Finally, a single fluorine resonance was observed in 19F methylene diphosphate analogues, reflecting a common set factors including the combined electronegativity and δπ-bonding possibilities for a β-P ligand which may lead to conformational changes in the phosphoryl chain. The resonance of carbon atom between β-P and γ-P showed a normal dependence to the electronegativity of substituent (Table 2). The downfield shifts increased in the series δ(CF2) > δ(CHF) > δ(CCl2) > δ(COHCH3) > δ(Br2) > δ(CHCl) > δ(CHBr) > δ(CH2). Finally, a single fluorine resonance was observed in 31P NMR spectra for both the difluoromethylene compound 1i (δ =−120.3 ppm, dd) and the mixture of diastereoisomeric monofluoromethylene compounds 1j (δ =−218.6 ppm, dd) showing that the fluorine environments could be considered as magnetically equivalent. Coupling constants were different for the two phosphorus nuclei directly bonded to the fluorinated β,γ-methylene bridge. 2JFP values for coupling with Pβ were greater than those for coupling with Pγ.

The substrate properties of these PMEA diphosphoryl derivatives were comparatively studied, in cell free solutions, towards HIV-1 reverse transcriptase. Indeed, it has been previously shown in various nucleotide series that chemical modifications on 5′-phosphate residues could preserve, in some cases, the terminating substrate properties of the triphosphate analogue in the DNA biosynthesis catalyzed by different polymerases. The substitution of β,γ-pyrophosphate by β,γ-phosphonates was rather systematically studied for a series of antiviral nucleoside analogues (AZT and 2′,3′-dideoxynucleosides) including modification of the triphosphate chain at the – position and presents some similarity with the compounds under study. Thus, in the particular case of (R) P- boronucleotide analogues of AZT, the order of activity towards the inhibition of HIV-1 reverse transcriptase is CF2 = O > CHF > CCl2 > NH > CH2,41 showing that the β,γ-difluoromethylene modification is effective and comparable to that of a natural bridge. However, the results obtained here demonstrate that none of the compounds 1b-j showed substrate properties towards HIV-1 reverse transcriptase till the concentration of 100 M (as example IC50 values for 1a and 1i were 6.4 ± 0.8 μM and 403 ± 75 μM, respectively). Even so, it is unpredictable, modifications of the nucleotide (either the sugar, base or 5′-triphosphate moieties) may affect its substrate activity through the modulation of its binding in the active site of the target enzyme or its incorporation.

Several factors including size, polarity, and electronegativity may modulate the activity, even so a certain tolerance of the HIV-1 reverse transcriptase to the γ-P-substituents was demonstrated in literature.42 To understand why diphosphate phosphonates analogues 1c, 1e, 1g and 1j are poor substrates of HIV-1 RT in comparison to PMEApp 1a, we performed modeling replacing the oxygen of the β,δ bridge of the diphosphate phosphonate by CH2, CCl2, CBr2 or CF2 groups, with respect to specific geometry and bond distances. According to Tuske et al.,43 amino acids R72 and K65, and D113 to a lesser extent, play a key role in the binding of the nucleotide in the active site and in their incorporation by HIV-1 RT (Figure 2(a)). If the substitution of oxygen atom of the, β,γ-pyrophosphate bond by a methylene group (CH2), i.e. compound 1c (Figure 2(b)), does not cause steric hindrance. However, the interaction with K65 (protonated form in the catalytic site) is lost and is responsible for nucleotide destabilization and discrimination. Indeed, the modification of its binding at the RT active site misaligns reactive centers and hampers the nucleophilic attack at the catalytic step of incorporation into viral DNA. When the O of the β,γ bridge is substituted by CCl2 or CBr2, respectively, in compounds 1e and 1g, the major drawback observed is the steric hindrance (Figure 2(c) and (d)). Indeed, distances between analogues 1e and 1g and amino acids K65 and D113 are less than 1.8 Å and this close vicinity is prompted to destabilize complex between the nucleotide and HIV-1 RT. When the O of the bridge is replaced by a CF2, i.e. compound 1i, the activity is somewhat restored. The steric hindrance is rather acceptable (Figure 2(c)) and distances with amino acids K65 and D113 are around 2.4 Å. The main benefit is that CF2 modification can establish electrostatic interactions with K65, counterbalancing the negative effect of the β,γ bridge modification.

Another important remark is the difference that can be observed when comparing the crystallographic
data from complexes of HIV-RT with purine or pyrimidine nucleotides. With purine nucleotides, as PMPApp, the amino acid R72 plays a crucial role in stacking the nucleobase, while only the amino acid R65 interacts with the O of the β,γ bridge. With pyrimidine nucleotides, their binding in the RT active site is slightly different, both amino acids R72 and K65 interact with the O of the α,β bridge and consequently the binding of the nucleotide is less sensible to the chemical modification of the bridge. This may explain why the modified phosphonate analogues of AZT are recognized and substrates for HIV-1 RT. Thus, they are efficiently incorporated in the growing nucleic acid chain.
Conclusion
Nine diphosphate analogues of PMEA have been designed as isostere of the parent diphosphorylated form, PMEApp. The benefit of stable P–C bonds replacing scissile P–O–C linkage constitutes an attractive interest to evaluate the electronic and stereochemical requirements for binding to relevant proteins. It was observed that HIV-RT does not extend the DNA primer with the synthesized compounds. Within this acyclic series, the replacement of the $\beta_{1,2}$ bridge of the diphosphate phosphonate by CH$_2$, CHCl, CCl$_2$, CHBr, CBr$_2$, CHF or CF$_2$ groups has a drastic effect on the recognition by the HIV-RT.

Authors' note
This article is dedicated to Dr. Gilles GOSSELIN on the occasion of his retirement.

Acknowledgments
We thank the “Fonds der Chemischen Industrie” for a postdoctoral fellowship (W. L.). We thank the “Agence Nationale de Recherche sur le Sida et les Hépatites Virales” for its financial support.

Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

Supplementary material
Supplementary material (synthetic procedure and compounds characterization) is provided as a separate electronic file (PDF format) and was submitted along with the manuscript.

References


